SONLICROMANOL

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H28N2O3
Molecular Weight	332.4372
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(C)C2=C(CC[C@](C)(O2)C(=O)N[C@@H]3CCCNC3)C(C)=C1O

InChI

InChIKey=LZYWLEPSQNXESC-KUHUBIRLSA-N

InChI=1S/C19H28N2O3/c1-11-12(2)17-15(13(3)16(11)22)7-8-19(4,24-17)18(23)21-14-6-5-9-20-10-14/h14,20,22H,5-10H2,1-4H3,(H,21,23)/t14-,19+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28916769 | https://khondrion.com/rd/

KH-176 is a drug candidate developed by pharmaceutical company Khondrion to treat a range of mitochondrial diseases including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders. KH176 has been granted Orphan Drug Designation for MELAS spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the USA. KH176 acts as a potent intracellular redox-modulating agent essential for the control of oxidative and redox pathologies.

Approval Year

PubMed

Title	Date	PubMed
The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders.	2019-01	30058726
Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease.	2017-09-15	28916769

Name

Type

Language

SONLICROMANOL

Official Name

English

KH-176

Preferred Name

English

(2S)-3,4-DIHYDRO-6-HYDROXY-2,5,7,8-TETRAMETHYL-N-(3R)-3-PIPERIDINYL-2H-1-BENZOPYRAN-2-CARBOXAMIDE

Systematic Name

English

sonlicromanol [INN]

Common Name

English

2H-1-BENZOPYRAN-2-CARBOXAMIDE, 3,4-DIHYDRO-6-HYDROXY-2,5,7,8-TETRAMETHYL-N-(3R)-3-PIPERIDINYL-, (2S)-

Systematic Name

English

KH176

Code

English

Code System Code Type Description

NCI_THESAURUS

C170380